- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07810647
Effectiveness of Shared Decision Making(SDM)on Patients With Poor Control Type 2 Diabetes (SDM)
Study Overview
Detailed Description
Background Diabetes and hyperglycemia not only increase the risk of complications of cardiovascular disease and lead to a situation involving exposure to danger of death. Meanwhile, the patient's self-management is one of the key factors affecting the quality control of blood sugar. Thereby, Shared Decision Making (SDM) is a patient-centered medical implementation method that healthcare professionals and patients jointly participate in treatment decision-making to reach a consensus, which can stimulate the health care ability of participants to achieve treatment goals.
Purpose: This research aims to implement the SDM model based on self-efficacy theory through individualized decision-making to strengthen the behavioral motivation of diabetic patients and finally, to improve the patient's health promotion behavior and the effectiveness of blood sugar control.
Method: Study Type: Interventional Actual Enrollment:76 participants Allocation:Randomized Intervention Model:Parallel Assignment Masking:Single(Participant)
Expected results:
It is hoped that the implementation of SDM model will be used to strengthen the behavioral motivation of diabetic patients through individualized decision-making, and to confirm whether it can effectively improve the patient's health behavior and the effectiveness of disease control.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Taiwan
-
Tainan, Taiwan, Taiwan, 709204
- An Nan Hospition-China Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged>20y/o
- Diagnosed by a physician as type 2 diabetes
- The Diabetes Participated in the Diabetes Shared Care Network
- Glycosylated hemoglobin (A1C)> 7.5%
- Can communicate in Chinese or Taiwanese.
Exclusion Criteria:
- People with mental or cognitive impairment who cannot communicate
- Health Literacy score lower than 6 points
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control group:as usual care
The control group received as usual care.
|
|
|
Experimental: Experimental group:The intervention of SDM
The experimental group received the intervention of SDM 3 times for 3 months,
|
The experimental group received the intervention of SDM 3times/month for 3months, then follow the health promotion behavior compliance by phone once a month.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diabetes self-efficacy scale
Time Frame: Pre-test (baseline)
|
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
|
Pre-test (baseline)
|
|
Diabetes self-efficacy scale
Time Frame: 1 months after intervnetion
|
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
|
1 months after intervnetion
|
|
Diabetes self-efficacy scale
Time Frame: 3 months after intervnetion
|
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
|
3 months after intervnetion
|
|
Diabetes health literacy scale
Time Frame: Pre-test (baseline)
|
A disease-specific scale to measure functional, communicative and critical health literacy in primary care
|
Pre-test (baseline)
|
|
Diabetes health literacy scale
Time Frame: 3 months after intervnetion
|
A disease-specific scale to measure functional, communicative and critical health literacy in primary care
|
3 months after intervnetion
|
|
Diabetes health promotion scale
Time Frame: Pre-test (baseline)
|
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
|
Pre-test (baseline)
|
|
Diabetes health promotion scale
Time Frame: 1 months after intervnetion
|
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
|
1 months after intervnetion
|
|
Diabetes health promotion scale
Time Frame: 3 months after intervnetion
|
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
|
3 months after intervnetion
|
|
Hemoglobin A1C (HbA1c) Test
Time Frame: 3 months after intervnetion
|
An HbA1c test shows what the average amount of glucose attached to hemoglobin has been over the past three months.
|
3 months after intervnetion
|
|
Hemoglobin A1C (HbA1c) Test
Time Frame: Pre-test (baseline)
|
An HbA1c test shows what the average amount of glucose attached to hemoglobin has been over the past three months
|
Pre-test (baseline)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FooyinU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.